Plasma adiponectin concentration is strongly associated with VLDL-TG catabolism in postmenopausal women

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 4, 2011, Pages 254-260

  Lapointe, A ^a   Tchernof, A ^b   Lamarche, B ^a   Piche M E ^a   Weisnagel, J ^b,c   Bergeron, J ^b   Lemieux, S ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

Adiponectin; Postmenopausal women; VLDL TG fractional catabolic rate

Indexed keywords

ADIPONECTIN; ADIPONECTIN, HUMAN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AGED; ARTICLE; BLOOD; BODY MASS; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; KINETICS; METABOLISM; MIDDLE AGED; OBESITY; POSTMENOPAUSE; SECRETION;

ADIPONECTIN; ADIPOSITY; AGED; BLOOD GLUCOSE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; KINETICS; LIPOPROTEINS, VLDL; MIDDLE AGED; POSTMENOPAUSE; TRIGLYCERIDES;

EID: 79952702756     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.10.007     Document Type: Article

References (33)

1. Goodpaster B.H., Krishnaswami S., Resnick H., Kelley D.E., Haggerty C., Harris T.B., et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 2003, 26:372-379.
2. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
3. Bjorntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990, 10:493-496.
4. Tremollieres F.A., Pouilles J.M., Cauneille C., Ribot C. Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 1999, 142:415-423.
5. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
6. Duncan B.B., Schmidt M.I., Pankow J.S., Bang H., Couper D., Ballantyne C.M., et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004, 53:2473-2478.
7. Ceddia R.B., Somwar R., Maida A., Fang X., Bikopoulos G., Sweeney G. Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 2005, 48:132-139.
8. Combs T.P., Berg A.H., Obici S., Scherer P.E., Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
9. Hung J., McQuillan B.M., Thompson P.L., Beilby J.P. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008.
10. Tschritter O., Fritsche A., Thamer C., Haap M., Shirkavand F., Rahe S., et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 2003, 52:239-243.
11. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
12. Ng T.W., Watts G.F., Farvid M.S., Chan D.C., Barrett P.H. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?. Diabetes 2005, 54:795-802.
13. Lohman T., Martorel R., Roche A. Standardization of anthropometric measurements 1988, Human Kinetics, Champaign, IL, p. 39-80.
14. Ferland M., Despres J.P., Tremblay A., Pinault S., Nadeau A., Moorjani S., et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr 1989, 61:139-148.
15. Piche M.E., Weisnagel S.J., Corneau L., Nadeau A., Bergeron J., Lemieux S. Contribution of abdominal visceral obesity and insulin resistance to the cardiovascular risk profile of postmenopausal women. Diabetes 2005, 54:770-777.
16. Expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl. 1):S5-20.
17. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
18. American Heart Association. Dietary guidelines for healthy American adults. A statement for physicians and health professionals by the nutrition committee, American Heart Association. Circulation 1988, 77:721A-724A.
19. Aarsland A., Chinkes D., Wolfe R.R. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J Clin Invest 1996, 98:2008-2017.
20. Gidez L.I., Miller G.J., Burstein M., Slagle S., Eder H.A. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res. 1982, 23:1206-1223.
21. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957, 226:497-509.
22. Yang L.Y., Kuksis A., Myher J.J., Steiner G. Origin of triacylglycerol moiety of plasma very low density lipoproteins in the rat: structural studies. J Lipid Res 1995, 36:125-136.
23. Patterson B.W., Zhao G., Klein S. Improved accuracy and precision of gas chromatography/mass spectrometry measurements for metabolic tracers. Metabolism 1998, 47:706-712.
24. Myher J.J., Kuksis A. General strategies in chromatographic analysis of lipids. J Chromatogr B Biomed Appl. 1995, 671:3-33.
25. Dagher F.J., Lyons J.H., Finlayson D.C., Shamsai J., Moore F.D. Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method. Adv Surg 1965, 1:69-109.
26. Adiels M., Taskinen M.R., Packard C., Caslake M.J., Soro-Paavonen A., Westerbacka J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
27. Tchernof A., Belanger C., Morisset A.S., Richard C., Mailloux J., Laberge P., et al. Regional differences in adipose tissue metabolism in women: minor effect of obesity and body fat distribution. Diabetes 2006, 55:1353-1360.
28. Avramoglu R.K., Basciano H., Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 2006, 368:1-19.
29. von Eynatten M., Schneider J.G., Humpert P.M., Rudofsky G., Schmidt N., Barosch P., et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 2004, 27:2925-2929.
30. Chan D.C., Watts G.F., Ng T.W., Uchida Y., Sakai N., Yamashita S., et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005, 51:578-585.
31. Qiao L., Zou C., van der Westhuyzen D.R., Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL-triglyceride catabolism. Diabetes 2008.
32. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
33. You M., Rogers C.Q. Adiponectin: a key adipokine in alcoholic fatty liver. Exp Biol Med (Maywood) 2009, 234:850-859.